libigran™ comprimate filmate 50 mg
deva holding a s - sildenafilum - comprimate filmate - 50 mg
libigran™ 100 mg comprimate filmate
deva holding a s - sildenafilum - comprimate filmate - 100 mg
norvir comprimate filmate 100 mg
abbvie ltd - comprimate filmate - 100 mg
prezista comprimate filmate 400 mg
johnson & johnson srl - darunavirum - comprimate filmate - 400 mg
prezista comprimate filmate 600 mg
johnson & johnson srl - darunavirum - comprimate filmate - 600 mg
prezista comprimate filmate 800 mg
johnson & johnson srl - darunavirum - comprimate filmate - 800 mg
sandimmun neoral solutie orala 100 mg/ml
novartis pharma ag - cyclosporinum - solutie orala - 100 mg/ml
yasmin comprimate filmate 3 mg + 0,03 mg
bayer pharma ag - drospirenonum + ethinylestradiolum - comprimate filmate - 3 mg + 0,03 mg
yaz comprimate filmate 3 mg + 0,02 mg
bayer ag - drospirenonum + ethinylestradiolum - comprimate filmate - 3 mg + 0,02 mg
adempas
bayer ag - riociguat - hipertensiune arterială, pulmonară - antihipertensive pentru hipertensiunea arterială pulmonară - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. eficacitatea a fost demonstrată într-un hap populației, inclusiv etiologii ale idiopatică sau ereditară pah sau htap asociată bolilor de țesut conjunctiv. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.